62. Paroxysmal nocturnal hemoglobinuria Clinical trials / Disease details

Clinical trials : 292 / Drugs : 151 - (DrugBank : 49) / Drug target genes : 22 - Drug target pathways : 108

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05476887 (ClinicalTrials.gov)	November 25, 2022	25/7/2022	To Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of KP104	An Open-label, Phase 2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of KP104 in Complement Inhibitor-naïve Subjects With Paroxysmal Nocturnal Hemoglobinuria (PNH)	Paroxysmal Nocturnal Hemoglobinuria	Drug: KP104	Kira Pharmacenticals (US), LLC.	NULL	Recruiting	18 Years	N/A	All	35	Phase 2	China
2	NCT05490017 (ClinicalTrials.gov)	December 30, 2020	4/8/2022	To Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Escalating Single and Multiple Doses of KP104	SYNERGY-1: A Phase 1 First-in-human, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Escalating Single and Multiple Doses of KP104 in Healthy Subjects	Paroxysmal Nocturnal Hemoglobinuria	Drug: KP104;Drug: Placebo	Kira Pharmacenticals (US), LLC.	NULL	Completed	18 Years	55 Years	All	80	Phase 1	Australia